Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 22;10(5):800.
doi: 10.3390/biom10050800.

Amaryllidaceae Alkaloids of Belladine-Type from Narcissus pseudonarcissus cv. Carlton as New Selective Inhibitors of Butyrylcholinesterase

Affiliations

Amaryllidaceae Alkaloids of Belladine-Type from Narcissus pseudonarcissus cv. Carlton as New Selective Inhibitors of Butyrylcholinesterase

Abdullah Al Mamun et al. Biomolecules. .

Abstract

Thirteen known (1-12 and 16) and three previously undescribed Amaryllidaceae alkaloids of belladine structural type, named carltonine A-C (13-15), were isolated from bulbs of Narcissus pseudonarcissus cv. Carlton (Amaryllidaceae) by standard chromatographic methods. Compounds isolated in sufficient amounts, and not tested previously, were evaluated for their in vitro acetylcholinesterase (AChE; E.C. 3.1.1.7), butyrylcholinesterase (BuChE; E.C. 3.1.1.8) and prolyl oligopeptidase (POP; E.C. 3.4.21.26) inhibition activities. Significant human BuChE (hBUChE) inhibitory activity was demonstrated by newly described alkaloids carltonine A (13) and carltonine B (14) with IC50 values of 913 ± 20 nM and 31 ± 1 nM, respectively. Both compounds displayed a selective inhibition pattern for hBuChE with an outstanding selectivity profile over AChE inhibition, higher than 100. The in vitro data were further supported by in silico studies of the active alkaloids 13 and 14 in the active site of hBuChE.

Keywords: Alzheimer’s disease; Amaryllidaceae; Narcissus pseudonarcissus cv. Carlton; alkaloids; butyrylcholinesterase; carltonine A–C; docking studies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structures of isolated alkaloids from Narcissus pseudonarcissus cv. Carlton.
Figure 2
Figure 2
Key 2D NMR correlations of compounds 1315.
Figure 3
Figure 3
Structures of newly isolated (13 and 14) and recently reported belladine-type AAs 6-O-demethylbelladine and 4′-O-demethylbelladine [37].
Figure 4
Figure 4
The hBuChE active site in complex with (R)-13 (in salmon, A,B) and (S)-13 (in purple, C,D) pseudo-enantiomers. All the amino acids exhibiting in the vicinity of the ligands up-to 6.0 Å are rendered. Hydrogen atoms of amino acids are omitted for clarity. Catalytic triad residues are shown in yellow, and amino acid residues in blue (A,C). In 2D diagrams (B,D), crucial amino acid residues are displayed in different colours depending on the nature of the interaction (e.g., purple for π-π, orange for anion-π, dark green for van der Waals contact, and light green for conventional hydrogen bond).
Figure 5
Figure 5
hBuChE active site in complex with (R)-14 (in green, A,B) and (S)-14 (in light-blue, C,D) pseudo-enantiomers. All the amino acids exhibiting in the vicinity of the ligands up-to 6.0 Å are rendered. Hydrogen atoms of amino acids are omitted for clarity. Catalytic triad residues are shown in yellow and amino acid residues in blue (A,C). In 2D diagrams (B,D), crucial amino acid residues are displayed in different colours depending on the nature of the interaction (e.g., purple for π-π, orange for anion-π, dark green for van der Waals contact, light green for conventional hydrogen bond).

Similar articles

Cited by

References

    1. Burns A., Jacoby R., Levy R. Psychiatric phenomena in Alzheimer’s disease. I: Disorders of thought content. Br. J. Psychiatry J. Ment. Sci. 1990;157 doi: 10.1192/bjp.157.1.72. - DOI - PubMed
    1. Nichols E., Szoeke C.E.I., Vollset S.E., Abbasi N., Abd-Allah F., Abdela J., Aichour M.T.E., Akinyemi R.O., Alahdab F., Asgedom S.W., et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88–106. doi: 10.1016/S1474-4422(18)30403-4. - DOI - PMC - PubMed
    1. Cimler R., Maresova P., Kuhnova J., Kuca K. Predictions of Alzheimer’s disease treatment and care costs in European countries. PLoS ONE. 2019;14:e0210958. doi: 10.1371/journal.pone.0210958. - DOI - PMC - PubMed
    1. Kumar A., Singh A., Ekavali A review on Alzheimer’s disease pathophysiology and its management: An update. Pharmacol. Rep. PR. 2015;67:195–203. doi: 10.1016/j.pharep.2014.09.004. - DOI - PubMed
    1. Hampel H., Mesulam M.-M., Cuello A.C., Farlow M.R., Giacobini E., Grossberg G.T., Khachaturian A.S., Vergallo A., Cavedo E., Snyder P.J., et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain J. Neurol. 2018;141:1917–1933. doi: 10.1093/brain/awy132. - DOI - PMC - PubMed

Publication types

LinkOut - more resources